Vaccine therapy for prostate cancer

Citation
Ba. Tjoa et al., Vaccine therapy for prostate cancer, UROL CLIN N, 26(2), 1999, pp. 365
Citations number
55
Categorie Soggetti
Urology & Nephrology
Journal title
UROLOGIC CLINICS OF NORTH AMERICA
ISSN journal
00940143 → ACNP
Volume
26
Issue
2
Year of publication
1999
Database
ISI
SICI code
0094-0143(199905)26:2<365:VTFPC>2.0.ZU;2-A
Abstract
Vaccine therapy may provide an alternative for prostate cancer patients who se disease no longer responds to hormone therapy. Administration of dendrit ic cells pulsed with prostate-specific membrane antigen (PSMA) induces cell ular immune responses against the tumor with virtually no adverse effects. About 30% of the evaluable patients were identified as partial responders, based on the National Prostate Cancer Project (NPCP) criteria. In addition, there was a 50% decrease of serum prostate-specific antigen or resolution of previously measurable lesions on imaging. Dendritic cell vaccine therapy may have a synergistic effect, when combined with other therapies.